arrow
P

Pilar Varela

hospital de cabueñes
H指数:30
被引数:2,735

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease

新诊断炎症性肠病患者生物制剂治疗、住院及手术的临床过程与预测因素:一项为期五年的前瞻性研究

2026-10-110
OAAI
Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study

先前生物制剂作用机制对炎症性肠病中抗TNF疗效的影响:一项ENEIDA注册研究

2026-08-120
PREAI
The Prevalence of Frailty in Elderly Inflammatory Bowel Disease Patients Varies Depending on the Scale Used

老年炎症性肠病患者衰弱症的患病率因所使用的量表而异

2026-08-010
PRE
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry

老年患者术后克罗恩病的治疗管理及预后比较研究:ENEIDA登记研究数据

2025-12-010
OAAI
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA

生物制剂治疗炎症性肠病中剂量递增和递减的频率与效果:ENEIDA中的RAINBOW-IBD研究

2025-08-080
PRE
Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study

自然病史、免疫学和遗传学特征,以及临床前期炎症性肠病(EARLY)的研究方案:一项前瞻性队列研究

2025-05-120
OA
Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry

有家族炎症性肠病史对生物制剂治疗时代儿童起病炎症性肠病患者免疫抑制剂、生物制剂使用及手术的影响。ENEIDA注册研究的结果。

2025-05-120
OA
Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
2025-01-220
PRE
Time-trends in the management of postoperative Crohn's Disease and its impact on long-term surgical recurrence. Data from the ENEIDA registry
2025-01-220
PRE
Real-World Outcomes of Upadacitinib in Crohn's Disease: Insights from ENEIDA database
2025-01-220
PRE
Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn's Disease. Data from the ENEIDA registry
2025-01-220
PRE
The Astur-Frailty-IBD Study: Prevalence and factors associated with Frailty in elderly patients with Inflammatory Bowel Disease.
2025-01-220
PRE
Real-world efficacy and safety of filgotinib in ulcerative colitis: results from the ENEIDA registry
2025-01-220
PRE
Postoperative recurrence after a definitive ostomy in Crohn's disease. A nationwide retrospective series from the Eneida registry
2025-01-220
PRE
Telemonitoring of Active Inflammatory Bowel Disease Using theApp TECCU:Short-Term Results of a Multicenter Trial of GETECCU
2024-11-180
OAAI
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
2024-09-172
OAAI
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project
2024-06-240
PRE
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

炎症性肠病患者从阿达木单抗原创者转换为阿达木单抗生物仿制药的真实世界结果: ADA-SWITCH研究

2023-04-238
PRE